Photo of Bishal Gyawali from oncology.queensu.ca
Oct 8, 2023, 18:03
Bishal Gyawali: Kudos to the FDA for being proactive and swift in making withdrawal recommendations in recent years.
Bishal Gyawali, Associate Professor at Queen’s University, shared on X/Twitter:
“When a drug that previously received AA is withdrawn swiftly following failure to prove clinical benefit in a confirmatory trial, it is not a failure of the system. It’s the opposite. It’s exactly how the system is supposed to function. Kudos to the FDA for being proactive and swift in making withdrawal recommendations in recent years. Things have meaningfully improved in recent days versus what they used to be when we studied this phenomenon in 2021.”
For the article click here.
Source: Bishal Gyawali/Twitter
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 1, 2025, 19:09
Apr 1, 2025, 18:48
Apr 1, 2025, 18:37